New combo therapy could speed up kidney stone passage

NCT ID NCT07310797

Recruiting now Symptom relief Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two medications, mirabegron and tamsulosin, to see which works best for helping people pass ureteral stones and reducing pain. 500 adults with stones between 4-10 mm will be randomly assigned to one of four groups: mirabegron alone, tamsulosin alone, both drugs together, or standard care. The main goal is to see how many stones pass within 4 weeks, along with pain levels and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mirabegron and Tamsulosin
What this could lead to: If successful, this could show that mirabegron, alone or with tamsulosin, helps pass kidney stones faster and reduces pain better than current standard care.
What could go wrong: This is a phase 4 trial, so the drugs are already approved, but results may not apply to all stone types or sizes. Side effects like low blood pressure or urinary issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for URETERAL CALCULI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ureteral Calculi ureterolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URETERAL CALCULI

Contacts and locations

Locations

Taipei Tzu Chi Hospital
RECRUITING

New Taipei City, 231, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.